Moderna and CEPI Partner to Advance mRNA Vaccine for Bird Flu: Revolutionizing Pandemic Preparedness
Moderna has secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support its research on a potential mRNA vaccine for bird flu. This funding will help Moderna advance its pandemic influenza vaccine candidate and contribute to its commitment to pandemic preparedness. The partnership with CEPI aims to accelerate the development of the bird flu vaccine candidate and enhance health security through mRNA technology, which can effectively address emerging health threats.
The Biden administration had initially announced a $590 million contract with Moderna in January to develop a vaccine for bird flu. However, the Department of Health and Human Services (HHS) later canceled this contract in May, creating uncertainty for the future of the bird flu vaccine candidate. Despite this setback, Moderna and CEPI are determined to explore alternative paths to advance the program and leverage mRNA technology to combat pandemic influenza.
CEPI's CEO, Richard Hatchett, emphasized the importance of the partnership in revolutionizing vaccine science and enhancing global health security. By harnessing the speed and adaptability of mRNA technology, the collaboration aims to expedite vaccine development, ensure scalability, and promote equitable access to vaccines. This strategic approach is crucial in safeguarding the world against future flu pandemics.
In conclusion, Moderna's collaboration with CEPI underscores the significance of innovative technologies in addressing public health challenges. The partnership not only accelerates vaccine research but also transforms the landscape of pandemic preparedness, paving the way for a more efficient and equitable response to global health threats.